Cellectis (NASDAQ:CLLS - Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22), Zacks reports. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The business had revenue of $33.22 million for the quarter, compared to analysts' expectations of $5.90 million.
Cellectis Price Performance
NASDAQ CLLS traded up $0.05 during mid-day trading on Tuesday, hitting $1.27. The stock had a trading volume of 240,147 shares, compared to its average volume of 136,677. The firm's 50 day moving average is $1.49 and its 200 day moving average is $1.79. Cellectis has a twelve month low of $1.14 and a twelve month high of $3.38. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The stock has a market capitalization of $70.59 million, a price-to-earnings ratio of -0.98 and a beta of 3.27.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on Cellectis in a research note on Thursday, February 27th. They issued a "buy" rating for the company.
Get Our Latest Stock Analysis on Cellectis
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More

Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.